• Bicycle Therapeutics PLC BCYC.OQ reported a quarterly adjusted loss of 88 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -62 cents. The mean expectation of twelve analysts for the quarter was for a loss of 84 cents per share. Wall Street expected results to range from -100 cents to -69 cents per share.

• Revenue rose 6.6% to $2.92 million from a year ago; analysts expected $7.78 million.

• Bicycle Therapeutics PLC's reported EPS for the quarter was a loss of $1.14​.

• The company reported a quarterly loss of $78.95 million.

• Bicycle Therapeutics PLC shares had risen by 7.3% this quarter and lost 46.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.8% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $24.50, about 69.6% above its last closing price of $7.46

This summary was machine generated from LSEG data August 8 at 01:54 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)